Wegovy for cardiovascular secondary prevention: the SELECT-trial coverage path

TLDR. The FDA expanded Wegovy's label in March 2024 to include cardiovascular event reduction in adults with established CVD and overweight or obesity (BMI 27 or higher). CMS followed by allowing Medicare Part D coverage of Wegovy when prescribed under the cardiovascular indication. The SELECT trial showed a 20 percent relative risk reduction in major adverse cardiovascular events on Wegovy 2.4 mg weekly. For Medicare patients with prior MI, prior stroke, or symptomatic PAD, the coverage route runs through the CV indication, not the obesity indication.

For two years before March 2024, Medicare did not cover Wegovy or any obesity drug for weight loss. The Medicare Modernization Act of 2003 excluded weight-loss drugs from Part D coverage. That exclusion is still in place. What changed is the labeling: Wegovy is now also a cardiovascular-event-reduction drug, which falls outside the weight-loss-drug exclusion.

The SELECT trial in one paragraph

SELECT enrolled 17,604 adults with established cardiovascular disease (prior MI, prior stroke, or symptomatic PAD) and BMI 27 or higher, randomized to semaglutide 2.4 mg weekly or placebo. Median follow-up 39.8 months. The primary endpoint, a 3-point MACE composite (CV death, non-fatal MI, non-fatal stroke), occurred in 6.5 percent of the semaglutide arm versus 8.0 percent of placebo, hazard ratio 0.80 (95 percent CI 0.72 to 0.90, p less than 0.001). Number-needed-to-treat to prevent one MACE event over the trial duration: approximately 67. All-cause mortality also dropped (HR 0.81). Trial design and breakdowns are detailed in our SELECT deep-dive.

The CMS coverage change

In March 2024, CMS issued guidance permitting Medicare Part D plans to cover anti-obesity medications when used to reduce the risk of major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity. Plans are not required to cover it. They are permitted to, and most have updated formularies accordingly.

For Wegovy specifically, the practical effect by mid-2026:

• Nearly all major Medicare Part D plans list Wegovy under the cardiovascular indication.
• Copay tiers vary, typically tier 3 specialty at $75 to $200 per month after deductible.
• Prior authorization requires documentation of the qualifying CVD diagnosis with appropriate ICD-10 coding.
• The Wegovy savings card is not available to Medicare patients (federal program restriction), so the Part D copay is the patient's actual cost.

The PA requirements

A Wegovy CV-indication PA requires:

• Established cardiovascular disease documentation. Acceptable diagnoses include prior MI (ICD-10 I21 or I25.2), prior ischemic stroke (I63), symptomatic peripheral artery disease (I73.9 with documented intermittent claudication or revascularization), or prior coronary revascularization (Z95.5 or Z95.61).
• BMI 27 or higher. Documented in the chart at the time of prescription.
• Prescription coded for cardiovascular risk reduction. The ICD-10 codes on the prescription must reflect the CV indication, not just the BMI. Prescribers who code only the obesity diagnosis on the script frequently see PA denials despite the patient qualifying clinically.
• Concurrent guideline-directed CV medical therapy. Statin (or documented intolerance), antiplatelet, antihypertensive as appropriate. Plans differ on whether they require this explicitly, but documentation of the broader CV care plan strengthens the request.

The diagnoses that do NOT qualify

The CV indication is for secondary prevention. Risk-factor profiles that do not establish CVD do not qualify under this pathway:

• Hypertension alone, even severe
• Hyperlipidemia alone, including elevated Lp(a)
• Type 2 diabetes alone (T2D has separate coverage routes for Ozempic, Mounjaro)
• Family history of premature CVD without personal events
• High coronary calcium score without symptoms or events
• Atrial fibrillation without an associated MI or stroke

Patients with these risk factors but no qualifying event are not SELECT-eligible. The CV indication does not cover them. Standard obesity-pathway coverage applies, which means Medicare patients in this category still cannot access Wegovy through Part D.

Where the commercial-insurance picture differs

Commercial insurance has covered Wegovy for obesity (with PA) since 2021. The CV indication adds a second route. For commercial patients:

• If you have BMI 30 or higher (or BMI 27 with comorbidity), the obesity route remains the easiest path.
• If you have established CVD and BMI 27 to 29, the CV indication unlocks coverage that the obesity route might have denied.
• If your commercial plan excludes obesity drugs (some self-funded employer plans do), the CV indication may still be covered as a CV drug.
• The Wegovy savings card remains available, capping commercial copays at $0 to $25 per month for many patients.

The cardiology routing question

Most Wegovy prescriptions still originate from primary care, obesity medicine, or endocrinology. Cardiology rarely prescribes Wegovy directly, even after the SELECT indication. The clinical pattern:

1. Cardiology manages the underlying CV disease, statins, antiplatelets, blood pressure.
2. Primary care or obesity medicine writes the Wegovy prescription under the CV indication after coordination with cardiology.
3. Cardiology supports the coding (the I25.10 or I21.xx ICD-10 documentation is in the cardiology chart) and may write a letter of medical necessity for appeals.

This is mostly a workflow consequence: cardiology offices are not set up for ongoing GLP-1 titration, but their charts contain the documentation that makes the PA work.

The cash-pay alternative

If insurance fails, NovoCare self-pay Wegovy is $499 per month with periodic promotional pricing. For patients without coverage who have meaningful CVD and BMI 27 or higher, the NNT of 67 over 40 months translates roughly to $20,000 to $30,000 in medication cost to prevent one MACE event. The cost-effectiveness analysis comes out favorable for high-risk patients, less so for lower-risk patients within the SELECT-eligible cohort.

Programs equipped for the CV indication

The CV indication requires accurate coding more than it requires specialty expertise. Programs that handle the documentation correctly:

• Form Health, obesity-medicine specialists with strong PA writing.
• Knownwell, primary-care-integrated, comfortable coordinating with cardiology.
• 9amHealth, cardiometabolic focus, common overlap with the SELECT-eligible population.

Programs primarily oriented toward cash-pay weight loss (Mochi, Hims) generally do not handle Part D CV PAs.

What the CV indication does NOT yet establish

The SELECT trial answered the secondary-prevention question for semaglutide. It did not answer several related questions that come up in clinical practice:

• Primary prevention. Patients with high CV risk but no established disease (high coronary calcium, high Lp(a), strong family history) were excluded from SELECT. Whether semaglutide reduces first MACE in this population is unknown. Several trials are exploring this. Until they report, Medicare and most commercial PAs require established CVD.
• Type 2 diabetes patients. T2D was excluded from SELECT. The cardiovascular benefit of semaglutide in T2D is established from earlier trials (SUSTAIN-6) at lower doses, but the SELECT-magnitude benefit in T2D-with-established-CVD has not been directly tested.
• Stroke prevention. The point estimate for non-fatal stroke in SELECT trended positive but did not reach significance. SELECT was not powered as a stroke-prevention trial specifically.
• BMI under 27. SELECT enrolled patients with BMI 27 or higher. The CV indication is limited to this BMI range. Normal-weight CV patients have no on-label pathway.
• Tirzepatide. SURPASS-CVOT will report tirzepatide cardiovascular outcomes in T2D. There is no comparable trial for tirzepatide in obesity-without-T2D-with-established-CVD. Treating the tirzepatide CV benefit as established at SELECT magnitude is extrapolation.

The CV-indication appeal pathway

When a CV-indication Wegovy PA is denied, the most common appeal pattern:

1. Re-submit with explicit ICD-10 coding for the qualifying CV event (I21.x for prior MI, I63.x for stroke, I73.9 with claudication or revascularization documentation for PAD).
2. Attach the cardiology note documenting the historical event.
3. Reference SELECT in the letter of medical necessity, noting that the patient meets SELECT inclusion criteria.
4. Note the FDA-approved indication and CMS coverage guidance from March 2024.
5. Document concurrent guideline-directed CV therapy (statin, antiplatelet, antihypertensive).

The peer-to-peer review with the plan's medical director is often the inflection point. For the broader appeal-letter template targeting CV-indication denials, see our not-medically-necessary appeal letter.

The transition from obesity to CV indication mid-treatment

A common situation: patient is on Wegovy under the obesity indication, has a cardiac event during treatment (MI, stroke), and the team wants to convert the indication to CV to access Part D coverage as the patient ages into Medicare or to strengthen the medical-necessity argument on a renewal. The mechanics:

• Update the diagnosis on the chart and prescription to reflect the new CV indication.
• Submit a new PA, not a renewal, because the indication has changed.
• Reference the CV event with date, hospital, and ICD-10 code.
• If transitioning to Medicare, this can happen during the standard plan-selection window or any qualifying event period.

The transition is procedurally easy when the documentation supports it. The conversation with the patient is often harder, because a new cardiac event has just occurred and the medication management is now downstream of a more serious clinical situation.

Frequently asked questions

Does Medicare cover Wegovy for weight loss alone in 2026?

No. The Medicare weight-loss-drug exclusion under the 2003 Medicare Modernization Act remains in place. Wegovy under the CV indication is covered as a cardiovascular drug, not as a weight-loss drug. Patients without qualifying CVD have no Part D access to Wegovy as of mid-2026.

What if I had a stroke 10 years ago, do I still qualify?

Yes. The CV indication does not have a time limit on the qualifying event. A prior MI or stroke at any point in the patient's history meets the established-CVD criterion, provided it is documented. The PA paperwork should reference the historical event with the date and the supporting record (hospital discharge summary, cardiology note).

Does Zepbound have a similar cardiovascular indication?

Not yet. The SURPASS-CVOT trial for tirzepatide is ongoing, with expected primary completion in 2027. Until that trial reads out and a label change is approved, Zepbound does not carry a CV-secondary-prevention indication. Medicare covers Zepbound under the OSA indication for moderate-to-severe obstructive sleep apnea, not for cardiovascular event reduction.

How long do I take Wegovy under the CV indication?

The trial duration was a median of 40 months and the benefit accrued continuously. Most clinicians treat the CV indication as long-term therapy, similar to how a statin is treated. Stopping Wegovy after weight loss has stabilized may be reasonable from a weight-control perspective but is not clearly supported from a CV-prevention perspective. There is no published trial of intermittent or short-course Wegovy for CV prevention.

What about all-cause mortality?

SELECT showed a 19 percent relative reduction in all-cause mortality (HR 0.81, 95 percent CI 0.71 to 0.93). This is a strong supporting endpoint and reduces concern that the MACE benefit is offset by harms elsewhere.

For the trial breakdown, see our SELECT MACE deep-dive. For the related comorbidity scenario where CV disease coexists with kidney disease, see T2D with CKD and ASCVD. For the Wegovy drug profile, see Wegovy. For the Medicare CV ranking of programs, see best for Medicare CV. For PA letter templates targeting the CV indication, see CV indication PA letter.

Citations

• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221-2232. nejm.org/doi/full/10.1056/NEJMoa2307563
• FDA approval letter for Wegovy supplemental indication, March 8 2024. fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
• CMS Memo, March 20 2024: Medicare Part D coverage of anti-obesity medications for established CVD. cms.gov/medicare/coverage/medicare-coverage-database
• Wegovy prescribing information, current label. accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf